Inovio Pharma (INO) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.13 +1.80%
EPS Growth %: +60.7%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +60.7%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.22), $0.05 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $125 thousand versus the consensus estimate of $339.28 thousand.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Obsidian Energy Increases Syndicated Credit Facility
- Green Dot and CommerceOne shareholders approve acquisition deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
